HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Lupin secures SBTi validation for emission reduction targets
Dec-16-2025

Lupin’s greenhouse gas (GHG) emissions reduction targets have been officially validated by the Science Based Targets initiative (SBTi). These validations cover all three emission scopes - Scope 1, Scope 2, and Scope 3 - aligning with the Paris Agreement to limit global temperature rise to 1.5 degree Celsius. This milestone underscores Lupin’s commitment to sustainability and decisive climate action, positioning the company among a select group that has achieved comprehensive SBTi validation within a year of setting its climate targets.

These goals are aligned with the 1.5 degree Celsius pathway and validated under SBTi’s latest guidelines, thereby positioning Lupin as a key participant in the global effort to combat climate change. 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. 

  RELATED NEWS >>